ST Wanbang announced that WP103, independently developed by Wanbond Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of the company, received written feedback from the US FDA's Class B meeting on the proposed key registered clinical trials. The FDA gave technical opinions on the phase II clinical trial plan and clarified the follow-up development path: after the company completes two animal tests, revises the clinical plan, and receives further approval from the FDA, it can promote the initiation of clinical trials, and the research data is intended to support new drug marketing applications. The drug has previously been certified as a rare pediatric disease and orphan drug by the US FDA. This progress will not have a significant impact on the company's business performance in the short term.

ST Wanbang announced that WP103, independently developed by Wanbond Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of the company, received written feedback from the US FDA's Class B meeting on the proposed key registered clinical trials. The FDA gave technical opinions on the phase II clinical trial plan and clarified the follow-up development path: after the company completes two animal tests, revises the clinical plan, and receives further approval from the FDA, it can promote the initiation of clinical trials, and the research data is intended to support new drug marketing applications. The drug has previously been certified as a rare pediatric disease and orphan drug by the US FDA. This progress will not have a significant impact on the company's business performance in the short term.